Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Anticipated 2022 Key Events:

Projected growth of approximately 50% in the Company's high-margin, recurring revenue stream from royalties to approximately $300 million driven by continued uptake of wave 2 launch products, subcutaneous DARZALEX® (daratumumab) and Phesgo® (pertuzumab, trastuzumab and hyaluronidase) utilizing ENHANZE® technology;
At least five new Phase 2/3 starts for existing ENHANZE® programs;
At least four new products utilizing ENHANZE® entering Phase 1 development by the Company's collaboration partners resulting in at least 20 products in development by end of 2022, compared to 16 at the end of 2021;
Data from ENHANZE® collaboration partner argenx SE for Phase 3 study of efgartigimod SC utilizing ENHANZE® technology in myasthenia gravis expected in the first half of 2022;
Investments to further drive revenue growth and extend revenue durability, including:
New, higher yield ENHANZE® API;
New rHuPH20, with extended room temperature stability, and with patent protection to 2032 in Europe and 2034 in the US;
At least one new global collaboration and license agreement for ENHANZE®, which is included in Company revenue guidance;
Up to $250 million in share repurchases, inclusive of $150 million accelerated share repurchase announced in December 2021, as part of the $750 million three-year share repurchase plan authorized by Halozyme's board of directors in December 2021 demonstrating the Company's continued commitment to a balanced capital allocation strategy.